In a series of recent developments, Sanofi ceased the provision of its high cholesterol drug in China due to scarce availability. However, Sanofi's teplizumab achieved MHRA's endorsement, instigating a transformation in type 1 diabetes treatment. Moreover, Tzield, another Sanofi drug for type 1 diabetes, also received MHRA approval. Sanofi's rillezabrutinib earned an orphan designation in the EU for IgG4-related disease. The company laid emphasis on its lab-to-market journey, with artificial intelligence and digital manufacturing and supply being key areas of focus.
Sanofi is also eyeing acquisitions, with its recent billion-dollar deal to procure a vaccine biotech and a $1.15 billion investment to buy biotech firm Vicebio. Additional highlights indicate bullish forecasts with strong sales growth predictions and resilience amid US tariff impacts. Several phase 3 studies for conditions such as multiple sclerosis, chronic lung associated disease, and advanced solid tumor treatments are underway. Notably, Sanofi's multiple myeloma treatment has been granted FDA orphan drug status.
Sanofi News Analytics from Mon, 06 Jan 2025 08:00:00 GMT to Sun, 17 Aug 2025 01:47:42 GMT - Rating 6 - Innovation 6 - Information 8 - Rumor -2
